1. NP23 leukemias exhibit Hox/Meis1 stem cell–like gene expression signatures that are enriched in human HSPC and AML genesets.
NP23 leukemias exhibit Hox/Meis1 stem cell–like gene expression signatures that are enriched in human HSPC and AML genesets. A, genes >1.5-fold overexpressed (red) or underexpressed (green) in AML, pre-T LBL, and pre–B1-ALL compared with WT BM, thymus, or spleen (Supplementary Table S3). Eighty-seven genes were overexpressed and 144 decreased independent of tissue type (Supplementary Tables S4 and S5). B, genes >1.5-fold overexpressed (red) or underexpressed (green) in NP23 BM, thymus, or spleen compared with WT controls. Note a core set of only five genes are overexpressed irrespective of tissue type (Supplementary Table S6). C, enrichment profiles of genes overexpressed in NP23 AML (identified in Fig. 3A) compared to human HSPC and early progenitor genesets, and D, human AML; right panel, leading edge genes from the FLT3-ITD geneset. E, a subset of GSEA leading edge genes overexpressed in NP23 AML and enriched in human HSPC, early progenitor and AML genesets. F, leading edge genes overexpressed in NP23 pre-T LBL and enriched in human leukemic genesets. NES, normalized enrichment score; FDR, false discovery rate.
Sheryl M. Gough et al. Cancer Discovery 2014;4:
©2014 by American Association for Cancer Research